ISBN: Outcomes No of Participants (studies) Follow up Quality of the evidence (GRADE) Relative effect Anticipated absolute effects Risk with Placebo Risk difference with Mineralocorticoid receptor antagonist (95% CI) Hyperkalaemia variousg LOWe, h due to risk of bias, inconsistency (from 12 more to 145 more) Renal function (change in creatinine (umol / L) - continuous) MODERATEe due to risk of bias The mean renal function (change in creatinine (umol / l) - continuous) in the control groups was The mean renal function (change in creatinine (umol / l) - continuous) in the intervention groups was Renal function (change in eGFR (ml/min/173m^2) - continuous) MODERATEe due to risk of bias The mean renal function (change in eGFR continuous) in the control groups was The mean renal function (change in eGFR (ml/min/173m^2) - continuous) in the intervention groups was Renal function (creatinine increased - dichotomous) VERY LOWb, e due to risk of bias, imprecision (from 19 fewer to 190 more) Renal function (30% reduction in eGFR MODERATEe due to risk of bias (from 58 more to 157 more) Renal impairment (not defined) 221 VERY LOWb,e due to risk of bias, imprecision (from 75 fewer to 36 more) Treating Heart Failure Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. 